TCL Archive DCBD Board Approves Recompetition Concepts, Including Cell Banks, Contrast Agents, Hepatoma Resources November 14, 1980
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
